Eddie Hickman
Stock Analyst at Guggenheim
(3.75)
# 712
Out of 5,152 analysts
21
Total ratings
80%
Success rate
32.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $87 → $90 | $74.90 | +20.16% | 10 | Feb 25, 2026 | |
| PMN ProMIS Neurosciences | Maintains: Buy | $125 → $35 | $24.79 | +41.19% | 4 | Feb 6, 2026 | |
| ATAI AtaiBeckley | Initiates: Buy | $11 | $3.54 | +210.73% | 1 | Jan 20, 2026 | |
| OTLK Outlook Therapeutics | Downgrades: Neutral | n/a | $0.43 | - | 4 | Aug 29, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $8.79 | +150.28% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $15.17 | +110.94% | 1 | Mar 13, 2025 |
Tarsus Pharmaceuticals
Feb 25, 2026
Maintains: Buy
Price Target: $87 → $90
Current: $74.90
Upside: +20.16%
ProMIS Neurosciences
Feb 6, 2026
Maintains: Buy
Price Target: $125 → $35
Current: $24.79
Upside: +41.19%
AtaiBeckley
Jan 20, 2026
Initiates: Buy
Price Target: $11
Current: $3.54
Upside: +210.73%
Outlook Therapeutics
Aug 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.43
Upside: -
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $8.79
Upside: +150.28%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $15.17
Upside: +110.94%